If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> RHEUMATOLOGY<br /> ISSN 2056-6395 Vol 4.1 • August 2017 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> EULAR 2017<br /> Madrid, Spain<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 4<br /> CONGRESS REVIEW.................................................................................................................................... 12<br /> • Review of the 18th European League Against Rheumatology (EULAR) Annual Congress of<br /> Rheumatology, held in Madrid, Spain, 14th–17th June 2017<br /> INTERVIEWS WITH EMJ RHEUMATOLOGY EDITORIAL BOARD…………………………………………...... 26<br /> SYMPOSIUM REVIEWS<br /> • BIOSIMILARS AND SWITCHING: WHAT IS YOUR PERSPECTIVE?.............................................. 34<br /> • SWITCHING PATIENTS FROM ORIGINATOR TO BIOSIMILAR MEDI<a title="EMJ Rheumatology 4.1 2017 page 1" href="http://viewer.zmags.com/publication/591c22a3?page=1"> RHEUMATOLOGY ISSN 2056-6395 </a> <a title="EMJ Rheumatology 4.1 2017 page 2" href="http://viewer.zmags.com/publication/591c22a3?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Rheumatology 4.1 2017 page 3" href="http://viewer.zmags.com/publication/591c22a3?page=3"> RHEUMATOLOGY • OSMOLYTES AS MEDIATORS OF THE </a> <a title="EMJ Rheumatology 4.1 2017 page 4" href="http://viewer.zmags.com/publication/591c22a3?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Dr Ian C. Chika</a> <a title="EMJ Rheumatology 4.1 2017 page 5" href="http://viewer.zmags.com/publication/591c22a3?page=5"> RHEUMATOLOGY AIMS AND SCOPE • The European</a> <a title="EMJ Rheumatology 4.1 2017 page 6" href="http://viewer.zmags.com/publication/591c22a3?page=6"> RHEUMATOLOGY 4.1 AUGUST 2017 Director Spencer G</a> <a title="EMJ Rheumatology 4.1 2017 page 7" href="http://viewer.zmags.com/publication/591c22a3?page=7"> Welcome Hello, and a warm welcome to this year</a> <a title="EMJ Rheumatology 4.1 2017 page 8" href="http://viewer.zmags.com/publication/591c22a3?page=8"> europeanmedical-journal.com EUROPEAN UNION Invest</a> <a title="EMJ Rheumatology 4.1 2017 page 9" href="http://viewer.zmags.com/publication/591c22a3?page=9"> Foreword Dr João Fonseca Lisbon Ac</a> <a title="EMJ Rheumatology 4.1 2017 page 10" href="http://viewer.zmags.com/publication/591c22a3?page=10"> European Medical Journal 2.1 2017 </a> <a title="EMJ Rheumatology 4.1 2017 page 11" href="http://viewer.zmags.com/publication/591c22a3?page=11"> FEATURE Climate Change: What Can Doctors Do? • </a> <a title="EMJ Rheumatology 4.1 2017 page 12" href="http://viewer.zmags.com/publication/591c22a3?page=12"> </a> <a title="EMJ Rheumatology 4.1 2017 page 13" href="http://viewer.zmags.com/publication/591c22a3?page=13"> EULAR ANNUAL CONGRESS 2017 IFEMA MADRID, </a> <a title="EMJ Rheumatology 4.1 2017 page 14" href="http://viewer.zmags.com/publication/591c22a3?page=14"> diseases, in this year 2016, and you all know wit</a> <a title="EMJ Rheumatology 4.1 2017 page 15" href="http://viewer.zmags.com/publication/591c22a3?page=15"> Dramatic Increase in Uptake of Pneumococcal Vacci</a> <a title="EMJ Rheumatology 4.1 2017 page 16" href="http://viewer.zmags.com/publication/591c22a3?page=16"> Dr Goulenok commented: “Our study has shown </a> <a title="EMJ Rheumatology 4.1 2017 page 17" href="http://viewer.zmags.com/publication/591c22a3?page=17"> New Drug Classes for the Treatment of Psoriatic A</a> <a title="EMJ Rheumatology 4.1 2017 page 18" href="http://viewer.zmags.com/publication/591c22a3?page=18"> Further research is required to verify the </a> <a title="EMJ Rheumatology 4.1 2017 page 19" href="http://viewer.zmags.com/publication/591c22a3?page=19"> Dr Nealon Lennox, University of Limerick, Li</a> <a title="EMJ Rheumatology 4.1 2017 page 20" href="http://viewer.zmags.com/publication/591c22a3?page=20"> New Tools Improve Early Diagnosis of Systemic Scl</a> <a title="EMJ Rheumatology 4.1 2017 page 21" href="http://viewer.zmags.com/publication/591c22a3?page=21"> Negligible Placental Transfer of Certolizumab Peg</a> <a title="EMJ Rheumatology 4.1 2017 page 22" href="http://viewer.zmags.com/publication/591c22a3?page=22"> Fluorescence Optical Imaging Outperforms Ultrasou</a> <a title="EMJ Rheumatology 4.1 2017 page 23" href="http://viewer.zmags.com/publication/591c22a3?page=23"> non-apparent joint inflammation of the hands and/o</a> <a title="EMJ Rheumatology 4.1 2017 page 24" href="http://viewer.zmags.com/publication/591c22a3?page=24"> Out of a total of 119 patients who reported back </a> <a title="EMJ Rheumatology 4.1 2017 page 25" href="http://viewer.zmags.com/publication/591c22a3?page=25"> In 2002, the new bDMARDs were incorporated into </a> <a title="EMJ Rheumatology 4.1 2017 page 26" href="http://viewer.zmags.com/publication/591c22a3?page=26"> Helena Canhão Invited Full Professor, Epidemiolo</a> <a title="EMJ Rheumatology 4.1 2017 page 27" href="http://viewer.zmags.com/publication/591c22a3?page=27"> I also mentioned, in the future we must look very</a> <a title="EMJ Rheumatology 4.1 2017 page 28" href="http://viewer.zmags.com/publication/591c22a3?page=28"> Q: What do you feel has been your greates</a> <a title="EMJ Rheumatology 4.1 2017 page 29" href="http://viewer.zmags.com/publication/591c22a3?page=29"> team, which led to the PubMed indexing and</a> <a title="EMJ Rheumatology 4.1 2017 page 30" href="http://viewer.zmags.com/publication/591c22a3?page=30"> the immunological mechanisms of the diseases and </a> <a title="EMJ Rheumatology 4.1 2017 page 31" href="http://viewer.zmags.com/publication/591c22a3?page=31"> Therefore, the best scenario to study </a> <a title="EMJ Rheumatology 4.1 2017 page 32" href="http://viewer.zmags.com/publication/591c22a3?page=32"> ...cartilage is not like a tyre on a car which ge</a> <a title="EMJ Rheumatology 4.1 2017 page 33" href="http://viewer.zmags.com/publication/591c22a3?page=33"> understandings of cartilage remodelling and follo</a> <a title="EMJ Rheumatology 4.1 2017 page 34" href="http://viewer.zmags.com/publication/591c22a3?page=34"> BIOSIMILARS AND SWITCHING: WHAT IS YOUR PERSPECTI</a> <a title="EMJ Rheumatology 4.1 2017 page 35" href="http://viewer.zmags.com/publication/591c22a3?page=35"> on biosimilars for both health professionals and </a> <a title="EMJ Rheumatology 4.1 2017 page 36" href="http://viewer.zmags.com/publication/591c22a3?page=36"> Prof Issacs provided the example of CT-P13 </a> <a title="EMJ Rheumatology 4.1 2017 page 37" href="http://viewer.zmags.com/publication/591c22a3?page=37"> In a recent editorial that he wrote with Jonathan</a> <a title="EMJ Rheumatology 4.1 2017 page 38" href="http://viewer.zmags.com/publication/591c22a3?page=38"> </a> <a title="EMJ Rheumatology 4.1 2017 page 39" href="http://viewer.zmags.com/publication/591c22a3?page=39"> Cross-reactivity between CT-P13 and IFX with </a> <a title="EMJ Rheumatology 4.1 2017 page 40" href="http://viewer.zmags.com/publication/591c22a3?page=40"> consider unsafe handling of biological agents tha</a> <a title="EMJ Rheumatology 4.1 2017 page 41" href="http://viewer.zmags.com/publication/591c22a3?page=41"> REFERENCES 1. World Health Organization. Guideli</a> <a title="EMJ Rheumatology 4.1 2017 page 42" href="http://viewer.zmags.com/publication/591c22a3?page=42"> SWITCHING PATIENTS FROM ORIGINATOR TO B</a> <a title="EMJ Rheumatology 4.1 2017 page 43" href="http://viewer.zmags.com/publication/591c22a3?page=43"> in treatment to patients influences the likelihood</a> <a title="EMJ Rheumatology 4.1 2017 page 44" href="http://viewer.zmags.com/publication/591c22a3?page=44"> results suggested that similar immunodominant</a> <a title="EMJ Rheumatology 4.1 2017 page 45" href="http://viewer.zmags.com/publication/591c22a3?page=45"> Of the 132 patients (16%) who discontinued </a> <a title="EMJ Rheumatology 4.1 2017 page 46" href="http://viewer.zmags.com/publication/591c22a3?page=46"> A recent example of how communication can s</a> <a title="EMJ Rheumatology 4.1 2017 page 47" href="http://viewer.zmags.com/publication/591c22a3?page=47"> to CT-P13 provided physicians with the confidence </a> <a title="EMJ Rheumatology 4.1 2017 page 48" href="http://viewer.zmags.com/publication/591c22a3?page=48"> After extensive research and in-depth analysis of</a> <a title="EMJ Rheumatology 4.1 2017 page 49" href="http://viewer.zmags.com/publication/591c22a3?page=49"> Watch our congress highlights from the 18th Europ</a> <a title="EMJ Rheumatology 4.1 2017 page 50" href="http://viewer.zmags.com/publication/591c22a3?page=50"> THE PATIENT’S PERSPECTIVE ON PSORIATIC ARTHRITIS:</a> <a title="EMJ Rheumatology 4.1 2017 page 51" href="http://viewer.zmags.com/publication/591c22a3?page=51"> is often delayed. There is no distinctive pattern</a> <a title="EMJ Rheumatology 4.1 2017 page 52" href="http://viewer.zmags.com/publication/591c22a3?page=52"> Physical function 90 Mental </a> <a title="EMJ Rheumatology 4.1 2017 page 53" href="http://viewer.zmags.com/publication/591c22a3?page=53"> will commonly base remission status on either the</a> <a title="EMJ Rheumatology 4.1 2017 page 54" href="http://viewer.zmags.com/publication/591c22a3?page=54"> on the disease, its progression, and its l</a> <a title="EMJ Rheumatology 4.1 2017 page 55" href="http://viewer.zmags.com/publication/591c22a3?page=55"> RISING TO THE CHALLENGE: PATIENT CASE STUDIES Cas</a> <a title="EMJ Rheumatology 4.1 2017 page 56" href="http://viewer.zmags.com/publication/591c22a3?page=56"> care practitioner41 and EULAR recommends </a> <a title="EMJ Rheumatology 4.1 2017 page 57" href="http://viewer.zmags.com/publication/591c22a3?page=57"> multidisciplinary European perspective on impr</a> <a title="EMJ Rheumatology 4.1 2017 page 58" href="http://viewer.zmags.com/publication/591c22a3?page=58"> Abstract Reviews PREVALENCE AND SIGNIFICANCE OF </a> <a title="EMJ Rheumatology 4.1 2017 page 59" href="http://viewer.zmags.com/publication/591c22a3?page=59"> EULAR 2017 and anti-La/SSB antibodies, associate</a> <a title="EMJ Rheumatology 4.1 2017 page 60" href="http://viewer.zmags.com/publication/591c22a3?page=60"> Abstract Reviews CD3 CD4 </a> <a title="EMJ Rheumatology 4.1 2017 page 61" href="http://viewer.zmags.com/publication/591c22a3?page=61"> EULAR 2017 Rheum Dis. 2016;75(1):16-22. </a> <a title="EMJ Rheumatology 4.1 2017 page 62" href="http://viewer.zmags.com/publication/591c22a3?page=62"> Abstract Reviews move our fingers. Through th</a> <a title="EMJ Rheumatology 4.1 2017 page 63" href="http://viewer.zmags.com/publication/591c22a3?page=63"> EULAR 2017 Table 1: Summary of increased and decr</a> <a title="EMJ Rheumatology 4.1 2017 page 64" href="http://viewer.zmags.com/publication/591c22a3?page=64"> Abstract Reviews to better understand the re</a> <a title="EMJ Rheumatology 4.1 2017 page 65" href="http://viewer.zmags.com/publication/591c22a3?page=65"> EULAR 2017 Citation: EMJ Rheumatol. 2017;4[1]:64</a> <a title="EMJ Rheumatology 4.1 2017 page 66" href="http://viewer.zmags.com/publication/591c22a3?page=66"> Abstract Reviews SLEEP DISORDERS IN FIBROMYAL</a> <a title="EMJ Rheumatology 4.1 2017 page 67" href="http://viewer.zmags.com/publication/591c22a3?page=67"> EULAR 2017 HF values at rest (p<0.05), showing</a> <a title="EMJ Rheumatology 4.1 2017 page 68" href="http://viewer.zmags.com/publication/591c22a3?page=68"> Abstract Reviews Table 2: Autonomic nerve system </a> <a title="EMJ Rheumatology 4.1 2017 page 69" href="http://viewer.zmags.com/publication/591c22a3?page=69"> EULAR 2017 Disclosure: Ms Nielsen and Dr Mo</a> <a title="EMJ Rheumatology 4.1 2017 page 70" href="http://viewer.zmags.com/publication/591c22a3?page=70"> Abstract Reviews 9 trials (with 16 comparisons) </a> <a title="EMJ Rheumatology 4.1 2017 page 71" href="http://viewer.zmags.com/publication/591c22a3?page=71"> EULAR 2017 Roche, Rottapharm-Madaus, Sobi, an</a> <a title="EMJ Rheumatology 4.1 2017 page 72" href="http://viewer.zmags.com/publication/591c22a3?page=72"> Abstract Reviews and four of the studies had no </a> <a title="EMJ Rheumatology 4.1 2017 page 73" href="http://viewer.zmags.com/publication/591c22a3?page=73"> EULAR 2017 these adverse events may be underesti</a> <a title="EMJ Rheumatology 4.1 2017 page 74" href="http://viewer.zmags.com/publication/591c22a3?page=74"> Abstract Reviews Table 2: Characteristics of pati</a> <a title="EMJ Rheumatology 4.1 2017 page 75" href="http://viewer.zmags.com/publication/591c22a3?page=75"> Would you like to write for the EMJ blog? Interac</a> <a title="EMJ Rheumatology 4.1 2017 page 76" href="http://viewer.zmags.com/publication/591c22a3?page=76"> EDITOR’S PICK In this intriguing art</a> <a title="EMJ Rheumatology 4.1 2017 page 77" href="http://viewer.zmags.com/publication/591c22a3?page=77"> lasts 6–8 weeks with reoccurrence being common. M</a> <a title="EMJ Rheumatology 4.1 2017 page 78" href="http://viewer.zmags.com/publication/591c22a3?page=78"> Notably, there are now >105 recogn</a> <a title="EMJ Rheumatology 4.1 2017 page 79" href="http://viewer.zmags.com/publication/591c22a3?page=79"> Since we each have thousands of at risk variants,</a> <a title="EMJ Rheumatology 4.1 2017 page 80" href="http://viewer.zmags.com/publication/591c22a3?page=80"> all one side of the tongue expressed </a> <a title="EMJ Rheumatology 4.1 2017 page 81" href="http://viewer.zmags.com/publication/591c22a3?page=81"> molecular variances that exist in one eye and not</a> <a title="EMJ Rheumatology 4.1 2017 page 82" href="http://viewer.zmags.com/publication/591c22a3?page=82"> 251-2. 34. 1000 Genomes Project Consortium; Auton</a> <a title="EMJ Rheumatology 4.1 2017 page 83" href="http://viewer.zmags.com/publication/591c22a3?page=83"> OSMOLYTES AS MEDIATORS OF THE MUSCLE TISSUE’S </a> <a title="EMJ Rheumatology 4.1 2017 page 84" href="http://viewer.zmags.com/publication/591c22a3?page=84"> blood vessels or muscle fibres acting as the prima</a> <a title="EMJ Rheumatology 4.1 2017 page 85" href="http://viewer.zmags.com/publication/591c22a3?page=85"> free amino acid in human tissues. It can either b</a> <a title="EMJ Rheumatology 4.1 2017 page 86" href="http://viewer.zmags.com/publication/591c22a3?page=86"> A 50 µm B 50 µm C </a> <a title="EMJ Rheumatology 4.1 2017 page 87" href="http://viewer.zmags.com/publication/591c22a3?page=87"> Table 1: Osmolytes in patients diagnosed with myo</a> <a title="EMJ Rheumatology 4.1 2017 page 88" href="http://viewer.zmags.com/publication/591c22a3?page=88"> currently still lacking effective treatment optio</a> <a title="EMJ Rheumatology 4.1 2017 page 89" href="http://viewer.zmags.com/publication/591c22a3?page=89"> dystrophy points to osmoregulation as a contribu</a> <a title="EMJ Rheumatology 4.1 2017 page 90" href="http://viewer.zmags.com/publication/591c22a3?page=90"> ADVANCES IN EPIGENETICS AND INTEGRA</a> <a title="EMJ Rheumatology 4.1 2017 page 91" href="http://viewer.zmags.com/publication/591c22a3?page=91"> prominent in CD4+ T cells. These data parallel a </a> <a title="EMJ Rheumatology 4.1 2017 page 92" href="http://viewer.zmags.com/publication/591c22a3?page=92"> Table 2: Use of omics in lupus to date. Methodolo</a> <a title="EMJ Rheumatology 4.1 2017 page 93" href="http://viewer.zmags.com/publication/591c22a3?page=93"> identify regions of open chromatin and thus</a> <a title="EMJ Rheumatology 4.1 2017 page 94" href="http://viewer.zmags.com/publication/591c22a3?page=94"> such as whole blood, provided there is informatio</a> <a title="EMJ Rheumatology 4.1 2017 page 95" href="http://viewer.zmags.com/publication/591c22a3?page=95"> patients, indicating that these chemokines m</a> <a title="EMJ Rheumatology 4.1 2017 page 96" href="http://viewer.zmags.com/publication/591c22a3?page=96"> interpretation first by experts in bioinformatics </a> <a title="EMJ Rheumatology 4.1 2017 page 97" href="http://viewer.zmags.com/publication/591c22a3?page=97"> and the susceptibility to autoimmunity. Epigeneti</a> <a title="EMJ Rheumatology 4.1 2017 page 98" href="http://viewer.zmags.com/publication/591c22a3?page=98"> NANOMEDICINES FOR INCREASED SPECIFICITY AND THERA</a> <a title="EMJ Rheumatology 4.1 2017 page 99" href="http://viewer.zmags.com/publication/591c22a3?page=99"> hydroxychloroquine, corticosteroid-related drugs,</a> <a title="EMJ Rheumatology 4.1 2017 page 100" href="http://viewer.zmags.com/publication/591c22a3?page=100"> resembling the RA condition, expecting a future t</a> <a title="EMJ Rheumatology 4.1 2017 page 101" href="http://viewer.zmags.com/publication/591c22a3?page=101"> defects, including RA.35 In order to enhance the </a> <a title="EMJ Rheumatology 4.1 2017 page 102" href="http://viewer.zmags.com/publication/591c22a3?page=102"> REFERENCES 1. Rubinstein I, Weinberg</a> <a title="EMJ Rheumatology 4.1 2017 page 103" href="http://viewer.zmags.com/publication/591c22a3?page=103"> europeanmedical-journal.com EUROPEAN UNION Invest</a> <a title="EMJ Rheumatology 4.1 2017 page 104" href="http://viewer.zmags.com/publication/591c22a3?page=104"> VITAMIN D DEFICIENCY AND CHRONIC WIDESPREAD PAIN </a> <a title="EMJ Rheumatology 4.1 2017 page 105" href="http://viewer.zmags.com/publication/591c22a3?page=105"> Table 1: Major causes of vitamin D deficiency. Dec</a> <a title="EMJ Rheumatology 4.1 2017 page 106" href="http://viewer.zmags.com/publication/591c22a3?page=106"> Table 2: Conditions and diseases causing chronic </a> <a title="EMJ Rheumatology 4.1 2017 page 107" href="http://viewer.zmags.com/publication/591c22a3?page=107"> synthesis. PTH increases the level of 1,25-(OH) D</a> <a title="EMJ Rheumatology 4.1 2017 page 108" href="http://viewer.zmags.com/publication/591c22a3?page=108"> as a neuroactive steroid, points to a relationshi</a> <a title="EMJ Rheumatology 4.1 2017 page 109" href="http://viewer.zmags.com/publication/591c22a3?page=109"> In the RCT conducted by Warner and Arnspiger,38 1</a> <a title="EMJ Rheumatology 4.1 2017 page 110" href="http://viewer.zmags.com/publication/591c22a3?page=110"> symptom response to cholecalciferol treatment:</a> <a title="EMJ Rheumatology 4.1 2017 page 111" href="http://viewer.zmags.com/publication/591c22a3?page=111"> 49. Kuru P et al. Hypovitaminosis D in wide</a> <a title="EMJ Rheumatology 4.1 2017 page 112" href="http://viewer.zmags.com/publication/591c22a3?page=112"> What’s New Pain in Psoriatic Arthritis Patients</a> <a title="EMJ Rheumatology 4.1 2017 page 113" href="http://viewer.zmags.com/publication/591c22a3?page=113"> Rheumatology Influence of Comorbidities in Psori</a> <a title="EMJ Rheumatology 4.1 2017 page 114" href="http://viewer.zmags.com/publication/591c22a3?page=114"> What’s New Differences Discerned Between Male and</a> <a title="EMJ Rheumatology 4.1 2017 page 115" href="http://viewer.zmags.com/publication/591c22a3?page=115"> Rheumatology However, as well as sex-sp</a> <a title="EMJ Rheumatology 4.1 2017 page 116" href="http://viewer.zmags.com/publication/591c22a3?page=116"> What’s New ≤20% in rheumatoid arthritis pati</a> <a title="EMJ Rheumatology 4.1 2017 page 117" href="http://viewer.zmags.com/publication/591c22a3?page=117"> Rheumatology the impact of BMI has been formally</a> <a title="EMJ Rheumatology 4.1 2017 page 118" href="http://viewer.zmags.com/publication/591c22a3?page=118"> UPCOMING EVENTS 45th Congress of the German Socie</a> <a title="EMJ Rheumatology 4.1 2017 page 119" href="http://viewer.zmags.com/publication/591c22a3?page=119"> RHEUMATOLOGY 19th Asia Pacific League of Associati</a> <a title="EMJ Rheumatology 4.1 2017 page 120" href="http://viewer.zmags.com/publication/591c22a3?page=120"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Rheumatology 4.1 2017 page 121" href="http://viewer.zmags.com/publication/591c22a3?page=121"> Buyer’s Guide • ABBVIE • AMGEN • BIOGEN • </a> <a title="EMJ Rheumatology 4.1 2017 page 122" href="http://viewer.zmags.com/publication/591c22a3?page=122"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NEW</a>